Biotech entity
Of the tracked stories, 2 of 2 also mention Cardinal Health, the most common co-covered peer. That works out to roughly 0.4 stories per week across a 36-day span. Each story carries 1.5 original sources on average, compared with 4.9 for the broader beat in this window.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Cardinal Health, the most common co-covered peer. That works out to roughly 0.4 stories per week across a 36-day span. Each story carries 1.5 original sources on average, compared with 4.9 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.5. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention McKesson, published between June 28, 2026 and August 2, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 158 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering McKesson. Shared-story counts are live from our verified record — not editorial picks.
Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Source: kjct8.com
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
McKesson is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
